659 filings
Page 11 of 33
6-K
3bamhbi66 dbbkv
1 Oct 19
Current report (foreign)
9:29am
6-K
ri86s5
26 Sep 19
Immutep Announces Expansion of Part A ofTACTI-002 Phase II Clinical Trial due to Positive Interim Data
9:05am
6-K
gnt0rj98 gu6bd
24 Sep 19
Immutep to Receive £4M Milestone Payment from GSK
12:00am
6-K
8s4yc cm3v9nr
18 Sep 19
Immutep Announces Japanese Patent Grant for LAG525 Antibody
12:00am
6-K
e58y1bz6z 65o
22 Aug 19
Immutep Granted European Patent for Eftilagimod Alpha In Cancer
6:04am
6-K
fb7f 8etd81mg
20 Aug 19
Preliminary final report
9:54pm
6-K
ywdn38yiio0eetx
14 Aug 19
Current report (foreign)
12:00am
6-K
vcq04 34gn9sbsq43
14 Aug 19
Not for release to US wire services or distribution in the United States
12:00am
6-K
f1lwj
7 Aug 19
Immutep Completes A$6M Entitlement Offer
12:00am
D
tms30ktbi rd
30 Jul 19
$520.67K in equity, sold $520.67K, 4 investors
7:15am
6-K
axhcawv
30 Jul 19
Quarterly report for entities subject to Listing Rule 4.7B
6:07am
6-K
a141bp6
5 Jul 19
Current report (foreign)
9:38pm
6-K
qek fjibq349
26 Jun 19
Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer
12:00am
6-K
xhupj1
21 Jun 19
Immutep Announces Australian Patent Granted for Eftilagimod Alpha
6:05am
6-K
wijc2bjrl1sjk1d
13 Jun 19
Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients forTACTI-002 Trial
6:16am
6-K
qrrx7voqx 5vrrhlhf
7 Jun 19
First patient received first dose in INSIGHT-004, a phase I clinical trial
12:00am
6-K
iur1f4a7l7x ue9l
5 Jun 19
Current report (foreign)
12:00am
6-K
y0zerglu1jf anrrrill
5 Jun 19
Immutep Presentation at ASCO 2019
12:00am
6-K
j5joaj327 cb18s0
23 May 19
Current report (foreign)
6:27am